Jeena Sikho Lifecare financials: Q1 FY27 due check

Why the stock is in social-media focus

Jeena Sikho Lifecare Ltd is being discussed online mainly around its latest quarterly performance and headline ratios. The scrip is referenced by its BSE and NSE identifiers in many posts, which helps retail investors cross-check they are tracking the same company. Users are circulating Q1 results highlights with revenue, operating profit, and profit after tax. Some posts also repeat market snapshot metrics like current price, 52-week high and low, and market capitalisation. The discussion also leans into business scale, especially the number of centres and beds. Dividend references are also appearing, including a historical dividend figure and a recommended final dividend for FY26. Several posts include debt and solvency style metrics such as debt to equity and net debt. Overall, the trend is a due diligence conversation anchored to reported financials rather than product news.

Trading identifiers and sector tags

Jeena Sikho Lifecare is shown as BSE: 544476 and NSE: JSLL in the shared context. The ISIN shared in posts is INE0J5801029. The company is repeatedly tagged under Healthcare and Pharmaceuticals and Drugs, with some posts also using Biotechnology and Drugs. These labels matter because investors tend to compare margins and valuation multiples against healthcare service providers and pharma peers. Social posts also quote the last earnings date as Q1 FY26-27 on 7 Aug, 2026. The same date is also repeated as an upcoming earnings date in some snippets, so readers should reconcile which calendar view they are looking at. A few posts show different market cap figures, including around Rs 6,708 crore and around Rs 6,513 crore. Price snapshots in the feed cluster around the mid-Rs 500s, including Rs 540 and other ticks like Rs 574.20 and Rs 555.20. This mix shows why ticker-level verification is a key first step in due diligence.

Operating footprint and expansion pipeline

A major part of the online bull and bear debate is about the company’s operating footprint. Posts describe Jeena Sikho Lifecare as an ayurvedic healthcare system provider in India. The network size shared is 119 active centres, broken into 61 hospitals and 58 clinics or day-care centres. The same summary says the footprint spans 23 states and over 100 cities or towns. Capacity is described as 2,300 operational beds. An additional 445 beds are described as being in the pipeline. These operational details are being used by investors to link financial growth to physical scale. Because this information is presented as a snapshot, readers typically verify it against official disclosures and the company website. Still, the repeated posting of these numbers suggests the footprint narrative is central to the current retail interest.

Q1 FY27 results: income, profit, margin

The Q1 result highlights being circulated put Total Income at Rs 224.40 crore. The same snapshot lists Operating Profit at Rs 76.68 crore and Profit After Tax at Rs 65.95 crore. An Operating Margin of 34.17% is also quoted in the highlights. Separate snippets repeat similar quarter figures in rounded form, stating revenue of Rs 224 and net profit of Rs 65. QoQ and YoY deltas are attached to the same quarter in the shared context, which is driving most of the quick comparisons. The quarter is also tied to the earnings date reference of 7 Aug, 2026. Below is a consolidated view of the Q1 numbers and percentage changes as shared in the posts. Investors should treat this as a social-media compilation and confirm it with the exchange filing.

QoQ and YoY trends discussed

A recurring due diligence angle is how growth and margin direction coexist in the same quarter. The context shows revenue growing YoY by 28.76% while also rising QoQ by 4.11%. Operating profit growth is shown as 10.96% YoY and 24.56% QoQ, which is being used to argue operating leverage. PAT growth is shown as 28.57% YoY and 44.85% QoQ in the snippets, drawing attention to bottom-line momentum. At the same time, operating margin is shown at 34.17% with a -13.82% figure alongside it, implying margin pressure compared with a prior base. Because margin changes can come from mix, costs, or accounting classification, this is one item that readers are flagging for closer checking in the official notes. The combination of rising profit and softer margin is not unusual in fast-scaling healthcare models, but the underlying driver needs confirmation from filings. Social feeds also list Gross Profit at around Rs 76 with growth percentages, which broadly aligns with the operating profit number shared elsewhere. The main takeaway from the trend discussion is that investors are focusing on quality of growth, not just the growth headline.

FY26 and Q4FY26 numbers quoted in posts

Alongside Q1, the feed contains a detailed FY26 and Q4FY26 block that users are referencing for context. Revenue from operations is stated at Rs 21,555.32 lakh in Q4FY26, with YoY growth of 54.80% versus Rs 13,925.06 lakh in Q4FY25. The same snippet says Q4FY26 revenue fell 2.76% QoQ from Rs 22,167.97 lakh in Q3FY26. For FY26, the same block states revenue increased 70.84% YoY to Rs 80,136.39 lakh versus Rs 46,907.19 lakh in FY25. Net profit is stated at Rs 4,507.77 lakh in Q4FY26, up 77.89% YoY versus Rs 2,533.97 lakh in Q4FY25. It also states Q4FY26 net profit fell 32.31% QoQ versus Rs 6,659.89 lakh in Q3FY26. On a full-year basis, FY26 net profit is quoted at Rs 22,169.81 lakh, up 177.32% YoY from Rs 7,994.33 lakh in FY25. One other social summary labels Q3FY26 results with very large “crore” figures alongside an EPS of Rs 5.37, so readers should verify units and source before using those numbers.

Balance sheet signals and net debt narrative

Several posts frame the balance sheet as strong and unlikely to face solvency or liquidity issues. A specific metric shared is debt to equity of 27.26%. Net debt is also discussed, with a claim that net debt is negative and becoming more negative over time. The context states latest net debt was -Rs 108.37 crore as of Mar-26, compared with -Rs 35.76 crore as of Mar-25. Negative net debt in social summaries is often used to signal surplus cash relative to borrowings, but it should be confirmed with the audited balance sheet and cash flow statement. A balance sheet table is also circulated showing growth in total liabilities and total assets up to Mar 2026, alongside lines for equity capital and reserves. Another part of the shared data references investments rising to 95 (unit not specified in the snippet), which investors are reading as a sign of cash deployment. Debtor days are mentioned as improving from 51.4 to 31.8 days, which is relevant for healthcare collections. These balance-sheet points are driving the “quality of earnings” side of the due diligence conversation.

Valuation, dividends, and quick diligence checks

Valuation snapshots differ across posts, so readers are seeing a range rather than a single clean figure. One block lists current price Rs 540, market cap Rs 6,708 crore, high and low Rs 850 and Rs 492, and P/E 28.4. Other snippets show P/E at 33.35 and also P/E at 27.53, plus price to book at 15.81 and PEG at 1.19. Profitability ratios repeated include ROCE 70.7% and ROE around 60.0%, with another snippet showing ROE 59.92%. Dividends are also a key topic, with one post stating a dividend of Rs 1.10 declared on 22 Sep, 2025. Another block says the board recommended a final dividend of Rs 4.50 per equity share of face value Rs 2 for FY 2025-26. Payout ratios are also discussed, including a latest dividend payout ratio of 14.99% and a 3-year average of 12.73%, alongside a separate statement of healthy payout at 19.1%. For basic diligence, social posts also share the registered office address in Zirakpur, Mohali, Punjab, plus a compliance contact email (cs@jeenasikho.co.in) and telephone (01762-513185). The most practical next step, based on what is trending, is to reconcile these headline metrics with the latest exchange filing and confirm that the units, periods, and per-share numbers match.